(MedPage Today) — TORONTO — Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data.
With a median follow-up of 3.9 months among 19 evaluable…
Source link : https://www.medpagetoday.com/meetingcoverage/ims/117570
Author :
Publish date : 2025-09-20 18:53:00
Copyright for syndicated content belongs to the linked Source.
